Navigation Links
Repligen Reports Second Quarter Fiscal Year 2009 Financial Results
Date:11/6/2008

will further the development, characterization and selection of a drug candidate for human clinical trials as well as support the development of tools ("biomarkers") to monitor the desired biological impact of the drugs in clinical trials.

Repligen is also studying this class of compounds in order to identify a potential treatment for Huntington's disease. Scientists at the Scripps Research Institute recently published results of a preclinical study demonstrating that HDAC inhibitors improved disease symptoms in a transgenic animal model of the disease. The study, entitled "The HDAC Inhibitor 4b Ameliorates the Disease Phenotype and Transcriptional Abnormalities in Huntington's Disease Transgenic Mice" was published in the Proceedings of the National Academy of Sciences.

Stock Repurchase Program

In June 2008, Repligen announced that its Board of Directors authorized the repurchase of up to 1.25 million shares of its common stock. To date, the Company has repurchased more than 350,000 shares for an aggregate cost of approximately $1.4 million.

Quarterly Conference Call

Walter C. Herlihy, Ph.D., will host a conference call and webcast on Thursday, November 6th at 10:00 a.m. EST, to review second quarter fiscal year 2009 financial results and expectations and provide a quarterly update of the Company. This call is being webcast and can be accessed via Repligen's website at http://www.repligen.com or you may also listen to the live broadcast by calling (866) 825-3209 for domestic calls and (617) 213-8061 for international calls. Participants must provide the following passcode: 62476438. For those who cannot participate in the live conference call, an archive of the audio webcast will be available shortly after the call and may be accessed at http://www.repligen.com.

About Repligen Corporation

Repligen Corporation is a
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder
2. Repligen Announces Conference Call of Second Quarter Fiscal Year 2009 Results Thursday, November 6th, 10:00 a.m. EST
3. Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors
4. Repligen Announces Share Repurchase Program
5. Repligen Announces Conference Call to Update Orencia(R) Lawsuit
6. Repligen Elects Earl Henry, M.D. to the Board of Directors
7. Repligen to Present at Upcoming Healthcare Conferences Wednesday, November 28th and Wednesday, December 5th
8. Repligen Reports Second Quarter Fiscal Year 2008 Financial Results
9. Stereotaxis Reports Third Quarter 2008 Financial Results
10. Volcano Reports 40 Percent Growth in Quarterly Revenues
11. Dialysis Corporation of America Reports Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 2014 Narrow networks that vary ... employers effective options to trim pharmacy costs and ... they can enhance formulary compliance and achieve savings ... that nearly all PBMs now include a narrow ... The Aug. 12 webinar from Atlantic Information ...
(Date:8/1/2014)... 01, 2014 Millions of women suffer ... legs and in some cases the arms, causing an ... about 17 million women in the U.S. alone are ... with the pain, embarrassment and discomfort caused by lipedema, ... physicians are unaware that this is a disease,” says Dr. ...
(Date:8/1/2014)... August 01, 2014 Get the report ... with PitchBook presents the 3Q 2014 Private Equity Breakdown ... equity investment, exits and fundraising activity in the second ... help plan for private equity endeavors for the remainder ... to download it now. , About Merrill DataSite , ...
(Date:7/31/2014)... 31, 2014 The 2013 edition ... about chemical listings, appellate decisions, litigation and settlement ... affect compliance with California's Proposition 65. , The ... law, regulations, history and trends impacting California's Proposition ... installment of the series which adds approximately 200 ...
(Date:7/31/2014)... recently used birth control pills containing high-dose estrogen and ... breast cancer, whereas women using some other formulations did ... , a journal of the American Association for Cancer ... oral contraceptives [birth control pills] in the past year ... to never or former oral contraceptive use, and that ...
Breaking Medicine News(10 mins):Health News:Atlantic Information Services Webinar to Offer Health Plan, Employer Strategies for Implementing Narrow Pharma Networks 2Health News:Lipedema Centers Works With Insurers To Gain Coverage For Lipedema Treatment 2Health News:Register to Download Merrill DataSite's Report: PitchBook 3Q 2014 Private Equity Breakdown Report 2Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2Health News:Recent use of some birth control pills may increase breast cancer risk 2
... , WHEATON, Ill., Nov. 24 Dr. Nelson Escobar, ... the recipient of the James Brady Award. The award ... of Illinois during their annual conference on October 30, 2009. ... was given the award in recognition of his expertise in ...
... The Union Labor Life Insurance Company ("Union Labor Life") ... nation,s largest vision benefits and services company, to provide a ... union employers and their members. , VSP has 40,000 doctor ... of optical frames and more. "We understand how important quality ...
... Nov. 24 Centene Corporation (NYSE: CNC ... has selected Centene as one of two Coordinated Care ... (MississippiCAN), a coordinated care program for Mississippi Medicaid beneficiaries. ... a contract in which the company will serve eligible ...
... that pose choking hazard, are too loud, or contain dangerous ... holiday shopping season begins, parents need to know that many ... United States. , That,s the conclusion of the 24th annual ... U.S. Public Interest Research Group (PIRG). , The report focuses ...
... and low-volume centers, study found , TUESDAY, Nov. 24 ... angioplasties necessarily produce the best results for patients? Maybe ... perfect" when it comes to artery-opening procedures, but a ... high-volume hospitals performing more or less equally. , The ...
... have found that hormones produced during pregnancy induce a ... This protein, alpha-fetoprotein (AFP), may serve as a viable, ... cancer, according to findings published in Cancer Prevention ... Cancer Research. "Hormones in pregnancy, such as ...
Cached Medicine News:Health News:Marianjoy Medical Group Physician Receives James Brady Award 2Health News:Union Labor Life & VSP Vision Care Align to Offer Vision Insurance Products 2Health News:Centene Corporation Receives Notification of Intent to Contract From the State of Mississippi 2Health News:Dangerous Toys Still on Store Shelves, Report Finds 2Health News:Dangerous Toys Still on Store Shelves, Report Finds 3Health News:Angioplasty Outcomes May Vary Little Between Hospitals 2Health News:Angioplasty Outcomes May Vary Little Between Hospitals 3Health News:Protein from pregnancy hormone may prevent breast cancer 2
(Date:7/31/2014)... DIEGO, July 31, 2014 Tandem Diabetes Care®, Inc. ... manufacturer of the t:slim® Insulin Pump, today reported its financial ... In comparing the second quarter of 2014 to the ... to $10.3 million from $5.5 million , t:slim Pump ... In comparing six months ended June 30, 2014 ...
(Date:7/31/2014)... July 31, 2014 Nektar Therapeutics (Nasdaq: ... quarter ended June 30, 2014. Cash and ... million as compared to $309.1 million at March 31, 2014."The ... Nektar as we look forward to significant milestones for a ... President and Chief Executive Officer of Nektar. "The first of ...
(Date:7/31/2014)... , July 31, 2014 Rock Creek Pharmaceuticals, ... it has initiated the development of its lead molecule, ... that it has selected Quotient Clinical, The Translational Pharmaceutics ... (UK) to run its early development programs. ... Application (CTA) by the end of the third quarter ...
Breaking Medicine Technology:Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4
... SUNNYVALE, Calif., Feb. 28, 2011 /PRNewswire/ ... company developing innovative technologies in diabetes management, announced that ... Silicon Valley Bank and ... used to help complete clinical trials and commercialize POGO™, ...
... Feb. 28, 2011 Advanced Cell Diagnostics, Inc. ... study utilizing RNAscope™ technology to detect human papillomavirus ... head and neck cancer. HPV status determined by ... patient outcome and highly concordant with that determined ...
Cached Medicine Technology:Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation 2Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation 3ACD Announces Clinical Study Results Using its RNAscope™ Technology 2ACD Announces Clinical Study Results Using its RNAscope™ Technology 3
Four disposable disc electrodes are pre-gelled and attached to wires in red, blue, black and green. 4mil carbon film, Ag/AgCl coated. Each package contains 20 individually sealed sets of four leads....
Representing the next step in the evolution of point-of-care testing, the i-STAT 1 Analyzer uses one platform to perform glucose strip testing along with all i-STAT test cartridges....
Lancet cut ultra sharp tip for low penetration resistance. Low noise and impedance level giving you a clear and reliable signal. Stainless steel needle, color coded attached lead wires. Needles sold ...
... bright xenon illumination for ... other instruments. Port allows ... optic cables. Worldwide voltage ... lamp change drawer ...
Medicine Products: